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Summary
Mechanical forces influence homeostasis in virtually every
tissue [1, 2]. Tendon, constantly exposed to variablemechan-
ical force, is an excellent model in which to study the conver-
sion ofmechanical stimuli into a biochemical response [3–5].
Herewe show in amousemodel of acute tendon injury and in-
vitro that physical forces regulate the release of active trans-
forming growth factor (TGF)-b from the extracellular matrix
(ECM). The quantity of active TGF-b detected in tissue
exposed tovarious levelsof tensile loadingcorrelatesdirectly
with the extent of physical forces. At physiological levels,
mechanical forces maintain, through TGF-b/Smad2/3-medi-
ated signaling, the expression of Scleraxis (Scx), a transcrip-
tion factor specific for tenocytes and their progenitors. The
gradual and temporary loss of tensile loading causes revers-
ible loss of Scx expression, whereas sudden interruption,
such as in transection tendon injury, destabilizes the struc-
tural organization of the ECM and leads to excessive release
of active TGF-b and massive tenocyte death, which can be
prevented by the TGF-b type I receptor inhibitor SD208. Our
findings demonstrate a critical role for mechanical force in
adult tendon homeostasis. Furthermore, this mechanism
could translate physical force into biochemical signals in
a much broader variety of tissues or systems in the body.Results
Tendon is a fibrous connective tissue made of specialized
fibroblasts called ‘‘tenocytes’’ and an abundant extracellular10These authors contributed equally to this work
*Correspondence: dusko.ilic@kcl.ac.uk (D.I.), sakait@ccf.org (T.S.)matrix (ECM), whose physiology and pathology depends
heavily on mechanical stimuli [3–5]. Tendon transfers contrac-
tion forces (tensile loading) from skeletal muscle to bone and
consequently possesses high tensile stiffness and strength.
Despite numerous studies, it is still largely unknown at molec-
ular levels how transmittal forces play a role in the regeneration
and maintenance of adult tendon.
During embryonic development, tenocytes originate from
mesodermal compartments, as do skeletal myoblasts, chon-
drocytes, and osteoblasts [6]. The basic helix-loop-helix tran-
scription factor Scx is found to be essential for tendon devel-
opment: Scx-deficient mice show a complete loss of major
force-transmitting and intermuscular tendons [7]. Although
multipotent mesenchymal progenitors might express Scx on
specific lineage commitment, only tendon progenitor cells
and tenocytes retain its expression, making Scx a highly
specific marker of tenogenic (precursor) cells and mature
differentiated tenocytes [8, 9].
ScxGFP Expression in Tenocytes of Adult Tendon
To understand the role that continuous transmittal force from
skeletal muscle to bone plays in adult tendon homeostasis,
we utilized a transgenic mouse strain that expresses the Scx
promoter-driven GFP marker (ScxGFP, Figures 1A and 1B)
[9]. Robust ScxGFP expression in a majority of tenocytes
(94.0%6 3.4%) clearly distinguished them from adjacent skel-
etal muscle cells in the myotendinous junction and from adja-
cent chondrocytes in cartilage (Figure 1B). ScxGFP expression
did not affect the tendon ECM composition, the expression of
collagen type I or type III, fibronectin, tenascin-C, small
leucine-rich proteoglycan fibromodulin or cartilage oligomeric
matrix protein (COMP or thrombospondin 5) (see Figure S1A
available online; data not shown). Scx expression specificity
was also confirmed in vitro. Primary tenocytes isolated from
10-week-old ScxGFPmice expressed high levels of GFP (Fig-
ure 1C), whereas primary chondrocytes and osteoblasts iso-
lated from newborn ScxGFP mouse ribs and calvaria were
negative (Figure 1C). As demonstrated with RT-PCR, adult
tenocytes expressed Scx and the mature tenocyte marker
tenomodulin [10], the major tendon ECM component collagen
type I, and the collagen receptors integrin alpha1 and integrin
alpha11 [11, 12]. In contrast, primary dermal fibroblasts iso-
lated from the same mice expressed neither Scx nor tenomo-
dulin, showing phenotypic differences between tenocytes and
nontendon fibroblasts in the adult. Neither cell type expressed
the chondrogenic master gene Sox9 [6] (Figure 1D). The
ScxGFP transgene can therefore be used to specifically iden-
tify and study adult tenocytes.
Effects of Acute Loss of Tensile Loading on ScxGFP
Expression and Tenocytes
The complete transection model was chosen to study tendon
injury because this model best mimics clinically acute tendon
injuries (i.e., definite interruption of tendon continuity and
immediate loss of tensile loading) (Table S1) [13, 14]. Almost
70% fewer tenocytes were found at 3 days posttransection
(17.5 6 2.5 cells/field in transected versus 56.8 6 3.3
in sham-operated tendons [n = 4; field = 0.037 mm2,
Figure 1. Loss of Tensile Loading Causes Tenocyte Cell Death in Adult Achilles Tendons
(A–D) Characterization of adult ScxGFP transgenic mice.
(A) Achilles tendons (Ac, arrows) in 10-week-old ScxGFP transgenic mice express a robust ScxGFP signal (green) under fluorescence stereomicro-
scopy.
(B) Histological analysis of Achilles tendons in 10-week-oldScxGFP transgenicmice. Hematoxylin and eosin (HE)-stained sections (left panels) and the same
areas with GFP/UV filters (right panels: green, ScxGFP; blue, DAPI [cell nuclei]). Top panels: adult Achilles tendon. Note that aligned tenocytes express
ScxGFP. Middle panels: Myotendinous junction at proximal Achilles tendon. ScxGFP is expressed only in tenocytes (arrow heads); myocytes (M) are
completely negative for ScxGFP. Bottom panels: Distal insertion of Achilles tendon. ScxGFP is expressed only in tenocytes. Chondrocytes (arrow heads)
at the calcaneus are completely negative for ScxGFP. Scale bars represent 50 mm.
(C) Only primary tenocytes from ScxGFP transgenic mice express ScxGFP in vitro. Left panels: phase contrast micrographs of primary tenocytes, chondro-
cytes and osteoblasts. Right panels: fluorescence micrographs of the same area with a GFP filter. Scale bar represents 100 mm.
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935p = 0.0003]), and only a small portion of the remaining cells
(11.7%) retained low ScxGFP expression posttransection (Fig-
ure 1E). Acute loss of tensile loading correlated with the loss of
tenocyte viability by as early as 0.5 hr after transection.
ScxGFP loss and gain of positive TUNEL gradually spread to
the proximal region of the transected Achilles tendon with
time (Figures 1F and 1G). Therefore a sudden loss of contin-
uous transmittal force from skeletal muscles leads to massive
death of tenocytes. This finding could explain why tendon
injuries very rarely heal. No obvious massive bleeding or
inflammatory response and no significant change in microvas-
cularity for at least up to 2 hr within tendon tissues after
complete transection was confirmed (Figures S1B–S1D).
Gradual Loss of Tensile Loading Allows Reversible Scx
Expression but Has Profound Effects on the Mechanical
Properties of Adult Tendons
Loss or attenuation of ScxGFP expression even in surviving te-
nocytes suggested that ScxGFP expression might depend on
mechanical signaling. To test that, we experimentally induced
a reversible gradual loss of continuous transmittal force from
skeletal muscles using botulinum toxin A. This toxin blocks
the release of acetylcholine specifically from presynaptic
motor nerve terminals and induces a gradual but reversible
skeletal muscle weakness, resulting in decreased muscle
force <25% of normal at 3 days postinjection, returning to
normal after 24weeks [15–19]. A single dose of botulinum toxin
A (6 U kg21 body weight) injected into the tricepsmuscle of 10-
to 12-week-old ScxGFPmice (Figure 2A) did not cause any cell
death (TUNEL-positive cells: 2 of 206 = 0.97% at 24 hr; 1 of
237 = 0.42% at 4 days). However, at 1 week postinjection the
number of tenocytes expressing ScxGFP decreased by
w79% and the level of expression was significantly lower
compared to that of saline-injected controls (Table S2 and
Figures 2A and 2B). Immunohistochemical analysis also
showed a significant decrease in the abundance of collagen
type I fibrils and COMP expression (Figures 2A and 2B).
Control saline-injected tendons showed no phenotypic
changes (data not shown).
Because Scx regulates the expression of pro-a1(I) collagen
(Col1a1) in tenocytes [20], the profound impact of tensile
loading on tenocyte cell viability and ScxGFP expression indi-
cated that even a gradual decrease in tensile loading could
affect the mechanical properties of adult tendons. Indeed,
at 1 week postinjection, tendons in toxin-injected mice
showed a significant decrease in stiffness (>3-fold) and
peak force (>2.5-fold) in comparison with control mice (p <
0.05; Figures 2C and 2D). Ultimate stress also decreased(D) RT-PCR analysis of gene expression profiles related to tendon and cartilag
Tenocytemarkers Scx and tenomodulin and chondrocyte markerSox9 are not e
type I; GAPDH, glyceraldehyde 3-phosphate dehydrogenase (as a control gen
(E–G) Acute tensile loading-loss model by complete transection of adult Achill
(E) Left panels: illustrations of the complete transectionmodel. Achilles tendon (
line in picture and red line in drawing, respectively). Middle and right panels:
3 days after operation. HE-stained sections and the same areas with GFP/UV
3 mm from calcaneus in both transected and intact tendons as shown in left
with normal intact adult tendon. Scale bar represents 50 mm.
(F) Analysis of cell death. Expression of ScxGFP (green; left panels), TUNEL sta
at 1, 2, and 24 hr after complete transection. Top panels: 1 hr after transection
edge of the tendon (arrows). Middle panels: 2 hr after transection. ScxGFP exp
proximal side of the Achilles tendon. Bottom panels: 24 hr after transection. Ext
Scale bar represents 100 mm.
(G) Analysis of TUNEL-positive cells in nontransected (control) and transected
*p < 0.05; **p < 0.001: significantly different compared to the number of posconsiderably at 1 week postinjection although without signif-
icance (p = 0.08; Figure 2D). At 2 weeks postinjection, tendons
from toxin-injected mice began to recover: the number of
ScxGFP-expressing tenocytes and the deposition of collagen
type-I and COMP increased (Figures 2A and 2B), and the
difference in stiffness and peak force compared to controls
was diminished (Figure 2D). Transmittal force from skeletal
muscles therefore has a major impact on adult tendon
homeostasis.
Mechanical Force Regulating ScxGFP Can Be Reversibly
Operated In Vitro
To determine how mechanical force regulates tenocyte func-
tion at the molecular level, primary tenocyte cultures were iso-
lated from adult ScxGFP mouse Achilles tendon (Figure 1C,
top panels). ScxGFPwas initially expressed in all primary teno-
cytes, but expression decreased to <30% after only 48 hr and
<5% by day 6 (Figures S2A and S2B). To quantify the force
required to retain ScxGFP expression, populations of primary
cultured ScxGFP tenocytes were simultaneously exposed to
different levels of mechanical force using a microfluidic
chamber system composed of multiple bifurcating networks
[21]. This fluid-flowdevice is amodel system that applies shear
stress to the tenocytes and mimics the response to mechan-
ical stimuli [22–24]. The level of mechanical force depended
on the location of cells in the chamber subdivisions, desig-
nated I to IV (Figure 3A). Shear stress values for these locations
in the chamber were obtained by solving Navier-Stokes (N-S)
equations using computational fluid dynamics software (COM-
SOL). The validity and applicability of equations and the
usefulness of software was verified by our group in separate
experiments involving microbeads [21]. There was agreement
between the velocity profiles predicted by the N-S equations
and experimental results using the technique of particle image
velocimetry. The fluid flow regime through the device was
laminar. As such, surface roughness or ECM accumulation
had negligible effects on wall shear stress and overall frictional
resistance. Only under turbulent flow conditions would ECM
accumulation and other factors that lead to changes in surface
‘‘roughness’’ have a significant effect [25]. Using an inlet flow
rate of 1 ml hr21 that resulted in an estimated shear stress
range of 0–0.60 dyne cm22, it was found that a stress of
0.14 dyne cm22 (area II) was optimal for retaining ScxGFP
expression in the primary tenocytes (Figures 3B and 3C). To
determine whether the decreased expression of ScxGFP after
6 days of culture was a reversible or an irreversible response,
primary tenocytes were then exposed to mechanical strain on
day 7. Tenocytes exposed to shear stress of 0.14 dyne cm22 ine in primary adult wild-type mouse tenocytes and dermal skin fibroblasts.
xpressed in skin fibroblasts. a1, a1 integrin; a11, a11 integrin; Col I, collagen
e).
es tendons.
Ac) was completely transected at 2mmproximal to the calcaneus (Ca) (white
histological analysis of intact (untreated) and transected tendon tissues at
filters (green, ScxGFP; blue, DAPI). Sections were prepared approximately
panels. Note that very few cells retain ScxGFP expression in comparison
ining (red; middle panels), and merged images (right panels) with DAPI (blue)
. ScxGFP expression is diminished, and TUNEL-positive cells appear at the
ression is significantly diminished, and TUNEL-positive cells expand to the
ensive cell death results in the formation of an acellular region (arrowheads).
tendons. Error bars represent standard deviation (n = 4; field = 0.07 mm2).
itive cells in control nontransected tendons.
Figure 2. A Gradual Tensile Loading-LossModel
by Local Injection of Botulinum Toxin A into Adult
Achilles Tendons
(A) Left panel: illustration of the botulinum toxin
treatment. The toxin (6 U kg21 weight) was in-
jected intramuscularly into medial and lateral
sides of the gastrocnemius muscle (asterisks).
Ac, Achilles tendon. Right panels: time course
of fluorescence micrographs in toxin-treated
Achilles tendons of ScxGFP mice (green,
ScxGFP; blue, DAPI; red, collagen type I and
COMP). Scale bar represents 50 mm.
(B) Analysis of ScxGFP, collagen type I, and
COMP intensities shown in (A). Relative fluores-
cence intensities are shown relative to each
control value of 100 (control tendon) (n = 5 for
each group). Error bars represent standard devi-
ation. *p < 0.05; **p < 0.01: significantly different
compared to controls.
(C) Biomechanical analysis of toxin-treated
tendon tissues. Left panel: resected Achilles
tendon (Ac, arrowheads) for biomechanical
experiments. Right panel: typical force-distance
curves in toxin-treated (botulinum toxin A, red
line) and saline-treated (sham, blue line) tendon
tissue at 1 week postinjection. Arrows indicate
peak force.
(D) Stiffness, peak force, and ultimate stress in
untreated tendons (control) and at 1 and 2 weeks
after toxin treatment. Error bars represent stan-
dard deviation (n = 5). Note that the toxin-treated
Achilles tendons exhibit significantly reduced
stiffness and peak force compared to untreated
controls at 1 week posttreatment although
ultimate stress is not significantly different.
*p < 0.05.
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(Figure S2C).
TGF-b and Mechanical Force Function to Maintain Scx
Expression, and Smad2/3 Plays an Essential Role in Both
Mechanical and Biochemical Signaling Pathways that
Regulate Scx Expression
Next, we examined 11 candidate cytokines/growth factors for
their role in regulating Scx expression in adult tenocytes [26–
32]. TGF-b1, -2, and -3 were the most potent and induced
similar levels of ScxGFP expression. GDF8 (myostatin, another
member of the TGF-b superfamily and a negative regulator of
skeletal muscle mass [33]) was w4-fold less potent than the
TGF-bs. Neither the osteoinductive cytokine BMP2 [34], used
as a negative control, nor any other cytokines/growth factors
examined had any effect. With each of these, the level of
ScxGFP expression dropped to that of untreated controls by
7 days of culture (Figure S2D).
In TGF-b superfamily-mediated signaling, all TGF-b ligands,
including TGF-b1, -2, -3, and GDF8, bind to cell surface TGF-btype I (designated as activin receptor-
like kinases [ALKs]) and type II
receptors. On ligand-binding, both
receptor types form heterotetrameric
complexes, which initiate downstream
Smad-signaling pathways [35, 36].
ScxGFP levels in tenocytes treated
with 1.0 mM of the TGF-b type I receptor
inhibitor SD208 [37] were significantlylower after 7 days of culture (24.4% 6 13.0%, p < 0.001)
compared to untreated controls (100%) (Figure 3D), and Scx
mRNA levels were downregulated to 28.0% 6 2.6% (p =
0.00045, Figure 3E). Although TGF-b is codependent on cyto-
skeletal tension in some cell types such as myofibroblasts
[38, 39], the addition of the cytoskeleton disrupting reagents
C3 transferase (an inhibitor of the Rho signaling pathway)
[40] or blebbistatin (an inhibitor of nonmuscle myosin II
production) [41, 42] did not affect TGF-b-mediated ScxGFP
expression in tenocytes (Figure S2E). These findings suggest
that in tenocytes TGF-b1 regulates Scx expression indepen-
dently of cytoskeletal tension, though this may need further
confirmation.
Because the TGF-bs bind to TGF-b type I receptor and acti-
vate the Smad2/3 pathway [35, 36], we examined the func-
tional relationship between mechanical force- and TGF-
b-mediated Scx induction. The addition of SD208 to primary
tenocytes under mechanical force resulted in significantly
(88.6%) decreased nuclear levels of phosphorylated Smad2
(pSmad2) in tenocytes. Phosphorylation of Smad2 was very
Figure 3. Mechanical Force and Smad2-Mediated Signaling Are Required for Maintenance of Scx Expression in Adult Tenocytes In Vitro
(A) Diagram ofmicrofluidic chamber and regions. The composition is a bifurcating network of several generations with areas (I–IV) of different shear stresses
(dyne cm22), as indicated by the color legend. A steady flow of cell culture medium from the input tube (left white circle) to the output tube (right black circle)
was supplied by a syringe pump. For a flow rate of 1 ml hr21, the wall mechanical strain in each area was about 0.1 (area I), 0.14 (area II), 0.30 (area III), and
0.60 (area IV) dyne cm22, respectively.
(B) ScxGFPexpression in primary tenocytes at 7 days under differentmechanical forces (flow rate, 1ml hr21). Note that tenocytes in areas II (0.14 dyne cm22),
III (0.30 dyne cm22) and IV (0.60 dyne cm22) retain ScxGFP expression, whereas tenocytes in untreated controls and area I (0.1 dyne cm22) show a marked
decrease in ScxGFP levels. Scale bar represents 50 mm.
(C) Analysis of ScxGFP intensities in primary tenocytes at 7 days under the different mechanical forces shown in (B). GFP intensity of untreated tenocytes at
7 days after culture (no shear) was set to 1.0. Relative GFP intensities of tenocytes determined in each area are shown relative to untreated control. Results
are themean of measurements for 100 cells in each area. Error bars represent standard deviation. ScxGFP levels in areas II, III, and IV are significantly higher
than those in untreated controls. *p < 0.05.
(D) Left panels: ScxGFP in primary tenocytes at 7 days under 0.14 dyne cm22 mechanical force with or without 1.0 mMTGF-b type-I receptor inhibitor SD208.
Note that SD208markedly inhibits mechanical force-mediated ScxGFP induction. Scale bar represents 100 mm. Right panel: analysis of ScxGFP intensities.
GFP intensity of tenocytes is shown relative to the control value of 100 (percent of control). Error bars represent standard deviation. Note that SD208 signif-
icantly (75.6%) inhibits mechanical force-mediated ScxGFP induction. *p < 0.001.
(E) Real-time PCR analysis of endogenous Scx mRNA expression in primary tenocytes at 7 days under 0.14 dyne cm22 mechanical force with or without
(control) 1.0 mM SD208. The intensity of Scx signals were normalized to that of 18S rRNA signals. Error bars represent standard deviation obtained by error
propagation (n = 3). Note that SD208 significantly (72.0%) downregulates mechanical force-mediated endogenous Scx mRNA expression, and this down-
regulation correlates with ScxGFP levels shown in (D). *p < 0.001.
(F) Effect of SD208 on pSmad2 levels in primary tenocytes from wild-type mice at 7 days under mechanical force with or without (control) 1.0 mM SD208 or
without shear stress. Top panels: expression of pSmad2 (green; left panels), nuclear staining with DAPI (blue; middle panels) and merged images (right
panels). Scale bar represents 25 mm. Bottom panel: analysis of pSmad2 intensities. The intensity is shown relative to the control value of 100 (control teno-
cytes under shear stress). Error bars represent standard deviation. *p < 0.001.
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937weak and pSmad2 was distributed diffusely, whereas
untreated tenocytes showed clear nuclear localization (Fig-
ure 3F). Furthermore, the Smad 3 inhibitor SIS3 [43] reduced
the expression of ScxGFP and Scx mRNA levels in bothTGF-b- and mechanical force-mediated systems by w35%
tow50% (Figure S2F). Therefore both TGF-b and mechanical
force have an important function in the maintenance of Scx
expression, and Smad2/3 plays an essential role in both
Figure 4. Sudden Interruption of Continuous Tensile Loading Destabilizes the ECM’s Structural Organization and Allows Consequent Release of a Signifi-
cant Amount of Active TGF-b
(A) Active TGF-b bioassay in culture media from adult tenocyte cell lines cultured in a single network chamber for 5 days under different mechanical forces.
Flow rate conditions for 60, 100, and 200 ml hr21 corresponded to 0.01, 0.015, and 0.03 dyne cm22 mechanical force, respectively. Culture medium (100 ml)
from each condition was used for the assay. The data show the amounts released in conditioned media for 1 hr under different flow rates. Luciferase activity
is presented as relative light units (RLU). Error bars represent standard deviation (n = 3). The values for active TGF-b released in the conditioned media over
Current Biology Vol 21 No 11
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939mechanical and biochemical signaling pathways that regulate
Scx expression.
Transection Interrupts Tensile Loading, Destabilizes ECM
Structural Organization, and Releases an Excess Active
TGF-b
In intact adult tissues and organs TGF-b is in a latent form
associated in a noncovalent complex with the ECM. In
response to injury, local latent TGF-b complexes are converted
into active TGF-b [44, 45]. To address how mechanical force
regulates TGF-b activation and release at a molecular level,
adult tenocyte cell lines were generated from Achilles tendons
of mice on p53- and p21-null genetic background [46] as the
yield of primary tenocytes was insufficient for analysis. These
null tenocytes were morphologically indistinguishable from
normal wild-type tenocytes (data not shown). When either
p53- or p21-null tenocytes were exposed to mechanical force
for 3 d in vitro, expression levels of TGF-b1 and Scx mRNAs
were remarkably upregulated (12.4 6 4.3 and 26.9 6 6.1 fold
[n = 3] respectively at 200 ml hr21 flow rate) compared to
untreated controls. Released active TGF-b levels in the culture
media corresponded to mechanical force strength (Figure 4A).
On the other hand, although adding 80 pM TGF-b1 into the
medium retained ScxGFP expression for up to 10 days, expo-
sure of primary tenocytes to 160 pM TGF-b1 led to cell death
in vitro (Figure 4B). We therefore hypothesized that the sudden
interruption of continuous tensile loading by complete tendon
transection might have resulted in the destabilization of the
ECM’s structural organization and consequent release of
excessive amounts of active TGF-b, which caused themassive
tenocyte death found in vivo (Figure 1F).
Indeed, subsequent analyses of collagen fibril ultrastructure
in transected tendons revealed irregular patterns by as early as
2 hr postinjury (Figure 4C). In intact tendon, the vast majority of
collagen fibrils were 60–120 nm in diameter (70.4%) and only
w2% of fibrils had a diameter <60 nm. By 2 hr postinjury, the
number of larger fibrils with diameter 60–120 nm had
decreased from 70% to 45%, whereas the number of thinner
fibrils (<60 nm diameter) increased 6.3-fold (12.5%). By 24 hr
postinjury, the collagen fibrils had deteriorated even further:
only w30% of fibrils with diameter 60–120 nm remained, and
the number of thinner fibrils (<60 nm diameter) had increased
to 30.6%. The number of fibrils with diameter >120 nm also
changed over time (16.1% in intact tendon, 30.8% at 2 hr,
and 20.6% at 24 hr postinjury). In contrast, unlike completely1 hr were 0.306 0.018 pM under 60 ml hr21 shear stress; 0.526 0.18 pM under
* denotes significantly different (p < 0.01) compared to the amount under str
(B) Effects of the cytokine TGF-b1 on primary tenocytes. Left and middle pa
a GFP filter for each condition. Right panels: the assessment of cell death by
kines were added for a further 7 days. Note that the addition of TGF-b1 at a l
contrast to other culture conditions, only a higher concentration (160 pM) le
Retention of ScxGFP expression was seen at TGF-b1 concentrations as low
FBS) nor 10% FBS maintained ScxGFP expression. Scale bars represent 10
(C) Ultrastructural analysis of collagen fibrils. Transmission electronmicrogra
(right panels) in intact (control), completely transected, and toxin-injected ad
fibril ultrastructure in tension-collapsing tendons by complete transection rev
represents 200 nm.
(D) Active TGF-b bioassay in intact (untreated) and transected (at 1.5 hr afte
sented as relative light units (RLU). Error bars represent standard deviation (n
of active TGF-b. *p < 0.05.
(E) Effects of SD208 on cell death in vivo after complete transection of adult
(green; middle panels) and merged images (right panels) with DAPI (blue) in i
or with 1.0 mM SD208 treatment. Scale bar represents 50 mm.
(F) Analysis of TUNEL-positive cells at 1.5 hr after complete transection witho
field = 0.07 mm2). Note that SD208 significantly attenuates tenocyte cell deatransected tendons, the relative distribution of fibrils of
different diameter in toxin-treated tendons did not change
dramatically over time (Figure 4C). Because fibronectin and fi-
brillin-1 associate with latent TGF-b binding proteins [44, 45],
their expression patterns were examined but no obvious
differences between transected and intact tendon tissues
were found (Figure S3). Quantitative analysis of active TGF-
b demonstrated that a significantly higher (w1.5-fold) concen-
tration was released into tissues at 1.5 hr postinjury relative to
uninjured tendon (p = 0.018; Figure 4D), whereas the total
amount of TGF-b indicated similar levels pre- versus postinjury
(631 6 61.1 relative light units [RLU] versus 651 6 69.0 RLU
[n = 3]). Such an excessive amount of active TGF-bwas indeed
related to tenocyte cell death in vivo after injury (Figure 4E).
The expression level of Scx mRNA at 1.5 hr postinjury was
36.4% 6 5.0% (n = 3) of nontreated control. The pretreatment
of tendons with 1.0 mM SD208 for 10 min before injury signifi-
cantly reduced TUNEL-positive cells, whereas massive teno-
cyte cell death was observed in the SD208-untreated control
transection (p < 0.001; Figures 4E and 4F). Thus the quantity
of released active TGF-b from ECM depends on changes in
mechanical force and demonstrates a mechanism underlying
massive tenocyte death in response to complete transection
of Achilles tendons.
Discussion
The present study (1) provides compelling evidence that
mechanical forces actually regulate expression of Scx through
activation of the TGF-b-/Smad2/3-mediated pathway, which,
in turn, is required for maintenance of tendon-specific ECM;
and (2) directly links an excess of active TGF-b released from
the ECM to adult tendon pathology.
An earlier study has demonstrated that myofibroblast
contraction activates and releases latent TGF-b from the
ECM in cultured fibroblasts [47]. This supports a functional
link between mechanical force and active TGF-b. In normal
physiological conditions, every cell senses mechanical signals
within a distinct range of magnitude [48]. After tissue injury
tissue boundaries disintegrate and ECM architecture is
considerably disrupted, causing dramatic mechanical imbal-
ance to cells [39]. Indeed, the elevated TGF-b activity in
response to injury causes delayed healing after bone fracture
and skeletal muscle injury [49, 50]. The suppression of TGF-b1
activity can promote functional recovery after corneal and100 ml hr21 shear stress; and 1.016 0.19 pM under 200 ml hr21 shear stress.
ain at 60 ml hr21 flow rate.
nels: phase contrast and fluorescence micrographs of the same area with
TUNEL staining (red). Primary tenocytes were cultured for 48 hr, then cyto-
ow concentration (2 ng ml21; 80 pM) retains the expression of ScxGFP. In
ads to tenocyte cell death (13.0 6 2.7 cells/field [n = 4; field = 0.15 mm2]).
as 20 pM (data not shown). Neither no addition (DMEM containing 1%
0 mm.
phs of transverse sections (left panels) andmorphometric analysis of fibrils
ult Achilles tendon tissues at 2 and 24 hr posttreatment. Note that collagen
eals irregular patterns by as early as 2 hr postinjury. Scale bar in left panel
r complete transection) adult Achilles tendons. Luciferase activity is pre-
= 3). Note that the transacted tendon tissues release significant amounts
Achilles tendon. TUNEL staining (red; left panels), expression of ScxGFP
ntact tendons and at 1.5 hr after complete transection without (untreated)
ut or with SD208 treatment. Error bars represent standard deviation (n = 4;
th. *p < 0.001.
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940spinal cord injury [49, 51]. Furthermore, after cancer radio-
therapy, TGF-b1 is overexpressed at the targeting sites that
develop injury-type response with cell death, excessive
fibrosis and tissue atrophy in the surrounding normal tissues
[52]. The alteration of mechanical integrity and the modifica-
tions that interfere with normal mechanotransduction to
mechanical strain could also be implicated in a wide disease
spectrum, including muscular dystrophies, arteriosclerosis,
osteoporosis and cancer [53]. Thus, the mechanism demon-
strated here opens new avenues for understanding how
mechanical force is converted into biochemical signals and
thereby determines cell fate in a variety of adult tissues or
systems in the body. Because multiple mechanisms exist in
mechanotransduction pathways, they will interplay as
complementary pathways to maintain tissue specific
phenotypes.
Tendon injuries are a serious clinical problem because
damaged tendon tissues heal slowly and rarely regain normal
mechanical strength [14, 30, 54]. These data imply that more
extensive use of physical modalities in therapy could benefit
patients and improve functional outcome. In tenocytes Scx
regulates transcription of Col1a1 through binding to tendon-
specific element 2 [20] and the induction of Scx expression
in injured tendon may support healing. Furthermore, the appli-
cation of TGF-b receptor inhibitors to injured tendons as a part
of the first-aid treatment immediately after injury could signif-
icantly improve the prognosis.Supplemental Information
Supplemental Information includes three figures, two tables, and Supple-
mental Experimental Procedures and can be found with this article online
at doi:10.1016/j.cub.2011.04.007.
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